يعرض 1 - 2 نتائج من 2 نتيجة بحث عن '"Dhamnaskar K"', وقت الاستعلام: 1.00s تنقيح النتائج
  1. 1
    Corrigendum: Zilucoplan, a macrocyclic peptide inhibitor of human complement component 5, uses a dual mode of action to prevent terminal complement pathway activation.

    المؤلفون: Tang GQ; UCB Pharma, Cambridge, MA, United States., Tang Y; UCB Pharma, Cambridge, MA, United States., Dhamnaskar K; Ra Pharmaceuticals, Cambridge, MA, United States., Hoarty MD; UCB Pharma/Ra Pharmaceuticals, Cambridge, MA, United States., Vyasamneni R; Ra Pharmaceuticals, Cambridge, MA, United States., Vadysirisack DD; UCB Pharma/Ra Pharmaceuticals, Cambridge, MA, United States., Ma Z; UCB Pharma/Ra Pharmaceuticals, Cambridge, MA, United States., Zhu N; UCB Pharma/Ra Pharmaceuticals, Cambridge, MA, United States., Wang JG; UCB Pharma, Cambridge, MA, United States., Bu C; UCB Pharma, Cambridge, MA, United States., Cong B; UCB Pharma, Cambridge, MA, United States., Palmer E; UCB Pharma, Cambridge, MA, United States., Duda PW; UCB Pharma, Cambridge, MA, United States., Sayegh C; UCB Pharma/Ra Pharmaceuticals, Cambridge, MA, United States., Ricardo A; Ra Pharmaceuticals, Cambridge, MA, United States.

    المصدر: Frontiers in immunology [Front Immunol] 2023 Sep 25; Vol. 14, pp. 1282155. Date of Electronic Publication: 2023 Sep 25 (Print Publication: 2023).

    نوع المنشور: Published Erratum

    بيانات الدورية: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: PubMed not MEDLINE; MEDLINE

    أضف إلى المفضلة
  2. 2
    دورية أكاديمية
    Zilucoplan, a macrocyclic peptide inhibitor of human complement component 5, uses a dual mode of action to prevent terminal complement pathway activation.

    المؤلفون: Tang GQ; UCB Pharma, Cambridge, MA, United States., Tang Y; UCB Pharma, Cambridge, MA, United States., Dhamnaskar K; Ra Pharmaceuticals, Cambridge, MA, United States., Hoarty MD; UCB Pharma/Ra Pharmaceuticals, Cambridge, MA, United States., Vyasamneni R; Ra Pharmaceuticals, Cambridge, MA, United States., Vadysirisack DD; UCB Pharma/Ra Pharmaceuticals, Cambridge, MA, United States., Ma Z; UCB Pharma/Ra Pharmaceuticals, Cambridge, MA, United States., Zhu N; UCB Pharma/Ra Pharmaceuticals, Cambridge, MA, United States., Wang JG; UCB Pharma, Cambridge, MA, United States., Bu C; UCB Pharma, Cambridge, MA, United States., Cong B; UCB Pharma, Cambridge, MA, United States., Palmer E; UCB Pharma, Cambridge, MA, United States., Duda PW; UCB Pharma, Cambridge, MA, United States., Sayegh C; UCB Pharma/Ra Pharmaceuticals, Cambridge, MA, United States., Ricardo A; Ra Pharmaceuticals, Cambridge, MA, United States.

    المصدر: Frontiers in immunology [Front Immunol] 2023 Aug 09; Vol. 14, pp. 1213920. Date of Electronic Publication: 2023 Aug 09 (Print Publication: 2023).

    نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

    بيانات الدورية: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE

    مواضيع طبية MeSH: Complement Activation* , Complement C5*/antagonists & inhibitors , Hemolysis*, Humans ; Antibodies, Monoclonal

    Full Text Finder
    أضف إلى المفضلة
أدوات البحث: أحصل على تغذية RSS – أرسل هذا البحث بالبريد الإلكتروني – حفظ البحث – جدول التنبيهات: لا شيء